+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Tumor Drug"

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H2 2018 - Product Thumbnail Image

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H2 2018

  • Drug Pipelines
  • October 2018
  • 109 Pages
  • Global
From
Gamma Secretase - Pipeline Review, H2 2020 - Product Thumbnail Image

Gamma Secretase - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 83 Pages
  • Global
From
Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H1 2020 - Product Thumbnail Image

Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H1 2020

  • Drug Pipelines
  • February 2020
  • 39 Pages
  • Global
From
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform - Pipeline Review, H1 2020 - Product Thumbnail Image

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform - Pipeline Review, H1 2020

  • Drug Pipelines
  • January 2020
  • 112 Pages
  • Global
From
Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2019 - Product Thumbnail Image

Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2019

  • Drug Pipelines
  • August 2019
  • 100 Pages
  • Global
From
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Pipeline Review, H2 2018 - Product Thumbnail Image

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Pipeline Review, H2 2018

  • Drug Pipelines
  • November 2018
  • 47 Pages
  • Global
From
Anti-Tumor Drugs Industry Forecasts - China Focus - Product Thumbnail Image

Anti-Tumor Drugs Industry Forecasts - China Focus

  • Report
  • November 2023
  • 107 Pages
  • China
From
Solid Tumor Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Solid Tumor Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • November 2023
  • 120 Pages
  • Global
From
Global and Chinese Neuroendocrine Tumors Drug Industry, 2021 Market Research Report - Product Thumbnail Image

Global and Chinese Neuroendocrine Tumors Drug Industry, 2021 Market Research Report

  • Report
  • January 2021
  • 141 Pages
  • China, Global
From
Gastrointestinal Stromal Tumor Drug Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Gastrointestinal Stromal Tumor Drug Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • May 2022
  • 101 Pages
  • Global
From
Gastrointestinal Stromal Tumor (GIST) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Gastrointestinal Stromal Tumor (GIST) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 155 Pages
  • Global
From
Neuroendocrine Tumors Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Neuroendocrine Tumors Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 157 Pages
  • Global
From
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 82 Pages
  • Global
From
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • June 2022
  • 81 Pages
  • Global
From
Paraganglioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Paraganglioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 42 Pages
  • Global
From
Wilms Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Wilms Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 43 Pages
  • Global
From
Biliary Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Biliary Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 52 Pages
  • Global
From
Neuroendocrine Gastroenteropancreatic Tumors Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Neuroendocrine Gastroenteropancreatic Tumors Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 59 Pages
  • Global
From
Hepatic Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Hepatic Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 38 Pages
  • Global
From
Germ Cell Tumors Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Germ Cell Tumors Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 47 Pages
  • Global
From
Loading Indicator

The Tumor Drug market is a subset of the Oncology Drugs market, which focuses on the development and sale of drugs used to treat cancer. These drugs are used to target and destroy cancer cells, reduce the size of tumors, and reduce the spread of cancer. Tumor drugs are typically divided into two categories: cytotoxic drugs, which kill cancer cells, and targeted therapies, which target specific molecules involved in cancer growth. These drugs are often used in combination with other treatments, such as radiation and surgery, to maximize the effectiveness of treatment. The Tumor Drug market is highly competitive, with many companies developing and selling drugs to treat cancer. Some of the major players in the market include Bristol-Myers Squibb, Merck, Pfizer, Novartis, and Roche. Other companies, such as AstraZeneca, Eli Lilly, and Amgen, are also active in the market. Show Less Read more